Relay Therapeutics, Inc. (RLAY)
17.96
-0.78
(-4.19%)
USD |
NASDAQ |
Oct 07, 16:00
17.98
+0.02
(+0.14%)
After-Hours: 20:00
Relay Therapeutics Enterprise Value : 3.215B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 3.215B |
| October 05, 2026 | 3.357B |
| October 02, 2026 | 3.263B |
| October 01, 2026 | 3.160B |
| September 30, 2026 | 3.064B |
| September 29, 2026 | 3.132B |
| September 28, 2026 | 2.986B |
| September 25, 2026 | 2.937B |
| September 24, 2026 | 2.994B |
| September 23, 2026 | 3.060B |
| September 22, 2026 | 3.348B |
| September 21, 2026 | 3.095B |
| September 18, 2026 | 3.237B |
| September 17, 2026 | 3.313B |
| September 16, 2026 | 3.237B |
| September 15, 2026 | 3.265B |
| September 14, 2026 | 3.285B |
| September 11, 2026 | 3.243B |
| September 10, 2026 | 3.248B |
| September 09, 2026 | 3.198B |
| September 08, 2026 | 3.296B |
| September 04, 2026 | 3.281B |
| September 03, 2026 | 3.274B |
| September 02, 2026 | 3.165B |
| September 01, 2026 | 3.160B |
| Date | Value |
|---|---|
| August 31, 2026 | 3.136B |
| August 28, 2026 | 3.222B |
| August 27, 2026 | 3.364B |
| August 26, 2026 | 3.372B |
| August 25, 2026 | 3.615B |
| August 24, 2026 | 3.438B |
| August 21, 2026 | 3.368B |
| August 20, 2026 | 3.425B |
| August 19, 2026 | 3.652B |
| August 18, 2026 | 3.624B |
| August 17, 2026 | 3.637B |
| August 14, 2026 | 3.460B |
| August 13, 2026 | 3.475B |
| August 12, 2026 | 3.506B |
| August 11, 2026 | 3.488B |
| August 10, 2026 | 3.477B |
| August 07, 2026 | 3.440B |
| August 06, 2026 | 3.436B |
| August 05, 2026 | 3.423B |
| August 04, 2026 | 3.390B |
| August 03, 2026 | 3.224B |
| July 31, 2026 | 3.235B |
| July 30, 2026 | 3.370B |
| July 29, 2026 | 3.134B |
| July 28, 2026 | 3.117B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group, Inc. | 2.152B |
| Karyopharm Therapeutics, Inc. | 205.83M |
| Spyre Therapeutics, Inc. | 6.056B |
| Akebia Therapeutics, Inc. | 292.28M |
| ACADIA Pharmaceuticals, Inc. | 2.515B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -83.71M |
| Revenue (Quarterly) | 0.35M |
| Total Expenses (Quarterly) | 84.06M |
| EPS Diluted (Quarterly) | -0.4127 |
| Gross Profit Margin (Quarterly) | -2.86% |
| Profit Margin (Quarterly) | -23.92K% |
| Earnings Yield | -8.73% |
| Normalized Earnings Yield | -8.726 |